Anthropic has released Claude Science, an AI-powered workbench designed to help medical researchers accelerate drug discovery by providing access to over 60 curated skills and connectors spanning life science disciplines. The tool is available to all Claude paid subscribers and aims to democratize AI-assisted pharmaceutical research beyond large corporations. Anthropic is also using Claude Science internally to pursue its own research and drug development programs focused on rare and neglected diseases.

What Makes Claude Science Different From General-Purpose AI?

Claude Science isn't a general chatbot adapted for biology. Anthropic designed it as an "AI workbench for scientists," built specifically for the unique demands of scientific research. Unlike general-purpose AI tools, Claude Science includes connectors and pre-built skills tailored to research workflows, allowing scientists to integrate data from multiple sources, run calculations, access specialized databases, and maintain rigorous documentation standards without constantly switching between different platforms.

The tool's availability to all Claude paid subscribers marks a significant shift in how AI companies approach pharmaceutical development. Rather than limiting advanced research tools to large pharmaceutical companies with massive budgets, Anthropic is making AI-assisted drug discovery accessible to smaller biotech firms, academic institutions, and independent researchers.

How Is Anthropic Using Claude Science for Its Own Research?

Beyond releasing the tool publicly, Anthropic is leveraging Claude Science to pursue internal research and drug development programs. The company has specifically targeted rare and neglected diseases, areas where traditional pharmaceutical development often struggles due to small patient populations and limited financial incentives. By combining AI-assisted research with internal expertise, Anthropic aims to identify promising drug candidates faster and more cost-effectively than conventional approaches.

This dual approach, where a technology company both releases tools to researchers and uses them internally, reflects a broader trend in AI-driven drug discovery. Companies are no longer waiting for perfect AI systems before applying them to real problems; instead, they build tools, test them on actual research challenges, and iterate based on results.

How to Leverage AI Workbenches in Your Research Practice

• Identify Research Bottlenecks: Determine which stages of your research process consume the most time, whether literature review, data analysis, target identification, or documentation, to understand where AI tools can provide the greatest acceleration.
• Evaluate Integration Compatibility: Check whether the AI tool connects to your existing databases, laboratory information management systems, and data repositories to ensure seamless workflow integration and minimize manual data entry.
• Start With Focused Pilot Projects: Test AI tools on smaller, well-defined research projects first to allow your team to learn the tool's strengths and limitations before scaling adoption across larger initiatives.
• Build Team AI Literacy: Invest in training your research team on how to effectively interact with AI workbenches, including how to structure requests clearly and ask targeted questions to get the best results.

Why AI Drug Discovery Is Moving From Promise to Practice

For years, AI in drug discovery has remained largely theoretical: faster identification of drug targets, better prediction of which compounds will work, reduced development timelines. Claude Science represents a shift from that promise toward tangible tools researchers can deploy today. The 60+ curated skills mean researchers don't have to figure out how to prompt an AI system from scratch; Anthropic has already built in domain-specific knowledge and workflows tailored to life science research.

The broader healthcare landscape is also accelerating AI adoption. Pharmaceutical companies, governments, and research institutions are investing heavily in AI-powered solutions across drug discovery, from logistics optimization to clinical trial management to drug target identification. Claude Science fits into this ecosystem as a tool that helps researchers leverage AI without requiring them to become AI engineers themselves.

"AI has the potential to rapidly accelerate the pace of drug discovery and the development of healthcare interventions," Anthropic noted in describing Claude Science's mission.

Anthropic

The practical impact of Claude Science will become clearer as researchers use it on actual drug discovery projects. Whether it genuinely accelerates the identification of promising drug candidates, helps researchers working on rare diseases find solutions faster, and becomes a standard tool in research labs worldwide will depend on real-world adoption and results over the coming months.